As most here know, I've been invested in IMGN sinc
Post# of 15624
To date, OWCP has had virtually no real successes, as I'd define success, i.e. improving the condition of people with diseases in human trials. I'd also define it in receiving full patent rights in major countries, especially the U.S. It should also be noted, they haven't had failures either, though they apparently have had to modify their patent filings, they have not been abandoned.
I believe that before a R/S occurs some degree of success needs to be seen. Patent approvals would certainly enhance the share price and validate the company's business plan. If they cannot gain patent approvals, they ought to do what other cannabis based companies are doing and just put products on the shelves in cannabis stores. On the other hand, if they gain the patent rights, then the possibility of a partner for the patented product greatly increases, the question becomes, how far do they take the patented product in clinical trials before attracting a partner. Clearly, the more they have to show the more a product will be worth, but it will also clearly cost more to get there as well. I don't believe stockholders should agree to any reverse split until they know we truly have a working business model. If we gain patent approvals I believe we'll also dramatically gain in stock price and at that point if a small reverse split makes sense, I could understand supporting it. I do not believe under any circumstances the outstanding shares should go below 50 million shares, that's 10% of the shares that are authorized.
Gary